Experimental drugs that directly inhibit the NSD2 enzyme have shown potential as an effective strategy against hard-to-treat cancers, such as lung and pancreatic tumors driven by KRAS mutations. The ...

Biopharma companies raised $34.89 billion through financings in the first seven months of 2025, including $5.66 billion in ...

Just two days after reporting the appointment of a new CEO, Instylla Inc. said it received a premarket approval from the U.S.

Ischemic stroke triggers a strong neuroinflammatory response, with microglial activation and neutrophil infiltration ...

Med-tech companies brought in $18.11 billion through financings in the first seven months of 2025, marking a modest rebound ...

Although congenital aortic valve disease (AVD) is one of the most prevalent types of congenital heart disease, affecting 1% ...

Proteinqure Inc. has received regulatory clearances from the U.FDA and Health Canada to initiate a phase I trial of lead ...

In the tumor microenvironment, cancer cells activate various signaling pathways to promote their growth. This includes the ...

The Nipah virus (NiV) from the Henipavirus genus is a bat-borne zoonotic pathogen that causes encephalitis and acute ...

Heartflow Inc. upped the price of shares in its IPO for a second time to $19 on Aug. 7 before opening on the Nasdaq as “HTFL” ...

Quantumpharm Inc., known as Xtalpi Inc., announced receiving $51 million up front from a potential $5.99 billion deal with ...

Location, location, location. While location is as important in manufacturing as it is in buying a home, it could become even ...